| |
Non-silica magbeads for superior cfDNA yields. MAGicBead’s novel DNA binding minimizes buffer volume, utilizes non-alcohol-based reagents, scales biofluid efficiently 0.2-10mL, and is compatible with open automation platforms. Beta Test Today!
|
|
Today's Big NewsMar 3, 2023 |
| By James Waldron Anyone looking for a roadmap out of the biotech bear market will take little comfort from Evaluate Vantage’s latest report. While Big Pharma valuations “regained their mojo” towards the end of last year, the outlook remains bleak for smaller-scaled drug developers. |
|
|
|
By Max Bayer Veru won't be receiving a EUA for its COVID treatment after all, the latest in a list of companies that missed the boat of softer regulatory waters. The company says that the FDA recommended that the company conduct a confirmatory trial, instead. |
By Nick Paul Taylor Praxis Precision Medicines isn’t letting a midphase fail stand in the way of its plans in essential tremor. While its selective T-type calcium channel blocker failed to beat placebo on the primary endpoint, Praxis zeroed in on secondary measures and post hoc analyses to make the case for further development. |
Sponsored by North Carolina Biotechnology Center Growth in North Carolina’s life sciences has outpaced most U.S. life sciences hubs. Top talent, infrastructure, and business-friendly climate are why companies are choosing the Tar Heel state. |
By Nick Paul Taylor Aeglea BioTherapeutics’ cost-cutting drive has had limited effect on its cash runway, with the biotech still barreling toward a fourth-quarter funding showdown despite recent cuts to its pipeline and head count. |
By Helen Floersh A TPD-based small molecule improved cognition and lowered pathological proteins and inflammatory cytokines in mice with Alzheimer's, suggesting the strategy might be worth pursuing. |
By Zoey Becker It's been three years since the FDA rejected BioMarin's Roctivian, but the company hasn't given up. After scoring a European nod last summer, BioMarin is marching toward a March 31 FDA decision date for its hemophilia A gene therapy. |
By Andrea Park Elon Musk said in November that Neuralink was mere months away from beginning in-human trials of its brain implant—a timeline that has now been cast into doubt. |
By Paige Minemyer Walmart Health is planning to nearly double the size of its footprint by the end of 2024, including a launch in two states and expansion in existing markets. |
By Teresa Carey This week on "The Top Line," we discuss 2022's M&A trends in the medtech sector and the surprising multibillion-dollar megadeals. We also cover the top headlines from this week. |
By Angus Liu Pfizer inked a manufacturing contract with Samsung Biologics. Olympus is buying a Korean endoscopic device maker as Dr. Reddy's boosts its U.S. generics portfolio. BeiGene's revenue climbed nearly 100% in 2022. And more. |
By Max Bayer,Gabrielle Masson Dunn-zo would be an apt term to summarize the top employment move this week. Billy Dunn, head of the Office of Neuroscience at the FDA, is leaving after 18 years at the agency. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss 2022's M&A trends in the medtech sector and the surprising multibillion-dollar megadeals. We also cover the top headlines from this week. |
|
|---|
|
|
| WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| WhitepaperThis paper describes the key elements of good US/EU corporate governance for US-based biopharma companies in operating Europe. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
